CRBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corbus Pharmaceuticals Holdings Inc (CRBP) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts in the form of analyst optimism and upcoming data updates, the lack of significant recent news, weak financial performance, and neutral trading sentiment suggest that waiting for more clarity or stronger signals would be prudent.
The MACD is slightly positive at 0.028, RSI is neutral at 59.682, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 10.087, with resistance at 10.557 and support at 9.617.
Analysts have raised price targets significantly, with Mizuho increasing it to $40 and Oppenheimer to $57, citing favorable risk/reward and upcoming data catalysts in 2026.
No significant recent news or congress trading activity. Financial performance remains weak with negative net income and EPS, despite YoY improvements.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but remains negative at -$20.55M. EPS also improved YoY but is still negative at -1.24.
Analysts are optimistic, maintaining Outperform ratings and raising price targets significantly. They highlight upcoming data updates in 2026 as key catalysts.
